Review



auclast  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc auclast
    Auclast, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pm40898858-56-5-6?v=Cell+Signaling+Technology+Inc
    Average 91 stars, based on 9 article reviews
    auclast - by Bioz Stars, 2026-07
    91/100 stars

    Images



    Similar Products

    auclast  (Cell Signaling Technology Inc)
    91
    Cell Signaling Technology Inc auclast
    Auclast, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pm40898858-56-5-6?v=Cell+Signaling+Technology+Inc
    Average 91 stars, based on 1 article reviews
    auclast - by Bioz Stars, 2026-07
    91/100 stars
    		  Buy from Supplier
    auclast of mbl  (MBL Life science)
    90
    MBL Life science auclast of mbl
    Auclast Of Mbl, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pm39245417-139-17-19?v=MBL+Life+science
    Average 90 stars, based on 1 article reviews
    auclast of mbl - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    remdesivir auclast  (Gilead Sciences)
    99
    Gilead Sciences remdesivir auclast
    Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating <t>remdesivir.</t> The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.
    Remdesivir Auclast, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pm38839047-134-35-35?v=Gilead+Sciences
    Average 99 stars, based on 1 article reviews
    remdesivir auclast - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    auclast örtengren 1979  (Ratiopharm gmbh)
    90
    Ratiopharm gmbh auclast örtengren 1979
    Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating <t>remdesivir.</t> The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.
    Auclast örtengren 1979, supplied by Ratiopharm gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pmc07696733__pharmaceutics___12___01074___s001-266-4-11?v=Ratiopharm+gmbh
    Average 90 stars, based on 1 article reviews
    auclast örtengren 1979 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    nabumetone 6 mna auclast  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health nabumetone 6 mna auclast
    Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating <t>remdesivir.</t> The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.
    Nabumetone 6 Mna Auclast, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/10__1097_slash_mjt__0000000000000158-81-0-32?v=Wolters+Kluwer+Health
    Average 86 stars, based on 1 article reviews
    nabumetone 6 mna auclast - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    cmax auclast fed/fasted ratios  (Sanofi)
    90
    Sanofi cmax auclast fed/fasted ratios
    Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating <t>remdesivir.</t> The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.
    Cmax Auclast Fed/Fasted Ratios, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pm24090732-237-2-10?v=Sanofi
    Average 90 stars, based on 1 article reviews
    cmax auclast fed/fasted ratios - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    auclast or auc∞  (Adis International Limited)
    90
    Adis International Limited auclast or auc∞
    Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating <t>remdesivir.</t> The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.
    Auclast Or Auc∞, supplied by Adis International Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pm23315355-103-11-34?v=Adis+International+Limited
    Average 90 stars, based on 1 article reviews
    auclast or auc∞ - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    auclast  (Glaxo Smith)
    90
    Glaxo Smith auclast
    Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating <t>remdesivir.</t> The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.
    Auclast, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/auclast/pm16001165-26-11-4?v=Glaxo+Smith
    Average 90 stars, based on 1 article reviews
    auclast - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating remdesivir. The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.

    Journal: The Journal of infectious diseases

    Article Title: Pharmacokinetics and Safety of Remdesivir in Pregnant and Non-Pregnant Women with COVID-19: Results from IMPAACT 2032.

    doi: 10.1093/infdis/jiae298

    Figure Lengend Snippet: Figure 1. Study design. The preinfusion period provided baseline data collection for 48 hours prior to initiating remdesivir. The infusion period included the initiation of RDV (200 mg on day 1 and 100 mg every 24 hours thereafter) for up to 5 or 10 days as clinically indicated. The safety follow-up period was inclusive of the time from discontinuing or completing remdesivir through 4 weeks after the last infusion. Among pregnant women (Arm 1), safety and birth outcomes were collected from the onset of labor or start of the cesarean delivery through 24 hours after delivery. The delivery visit could occur during remdesivir treatment, safety follow-up, or afterward. Except for PK sampling, study procedures and data collections were largely performed by medical chart abstraction or remote contact. Abbreviations: EOI, end of infusion; IV, intravenous; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; RDV, remdesivir.

    Article Snippet: Plasma Pharmacokinetic Parameters for Remdesivir, GS-704277, and GS-441524 and Protein Binding by Study Arm PK Parameters Pregnant (n = 21) Nonpregnant (n = 22) GMR (90% CI) Infusion duration, ha 1.0 (0.5–1.28) 1.0 (0.5–2.0) ... Remdesivir AUClast, ng · h/mL 1132 (85.7) 1190 (82.7) 0.95 (0.65–1.38) AUC0-24h, ng · h/mL 1247 (87.2) 1303 (49.2) 0.96 (0.67–1.37) Cmax, ng/mL 1360 (108) 1237 (111) 1.10 (0.70–1.73) Tmax, h 1.17 (0.60–1.31) 1.08 (0.66–1.53) 0.86 (0.64–1.15) t1/2, h 1.01 (36.0) 1.09 (36.4) 0.92 (0.75–1.13) CL, L/h 80.2 (87.2) 79.6 (47.4) 1.01 (0.70–1.45) Vd, L 118 (89.8) 125 (57.4) 0.94 (0.63–1.39) GS-704277 AUClast, ng · h/mL 408 (47.8) 424 (35.5) 0.96 (0.78–1.18) AUC0-24h, ng · h/mL 454 (29.8) 437 (36.2) 1.04 (0.88–1.23) Cmax, ng/mL 217 (41.4) 213 (34.1) 1.02 (0.85–1.23) Tmax, h 1.18 (0.62–1.36) 1.08 (0.66–1.46) 0.99 (0.79–1.24) t1/2, h 1.33 (19.9) 1.23 (30.0) 1.08 (0.95–1.23) GS-441524 AUClast, ng · h/mL 1842 (31.9) 2065 (36.0) 0.89 (0.75–1.06) AUC0-24h, ng · h/mL 1836 (32.2) 2046 (37.7) 0.90 (0.75–1.07) Cmax, ng/mL 113 (27.8) 121 (32.0) 0.93 (0.80–1.09) Tmax, h 2.1 (2.0–3.4) 2.9 (2.0–4.7) 0.77 (0.61–.97) t1/2, h 20.0 (28.6) 20.3 (30.3) 0.96 (0.82–1.18) C24h, ng/mL 51.6 (38.5) 57.1 (44.1) 0.90 (0.73–1.12) Protein binding Remdesivir free fraction, % 3.43 (22.8) 3.22 (26.2) 1.06 (0.95–1.19) Albumin, g/L 28.0 (26.0–30.0) 36.0 (33.5–38.0) 0.70 (0.56–.86) AAG, mg/dL 94.6 (77.2–144.3) 124.4 (98.9–172.4) 0.73 (0.60–.88) Data presented as geometric mean (CV%), except infusion duration which is reported as median (range), and Tmax, albumin, and AAG which are reported as median (IQR).

    Techniques: Sampling, Drug discovery

    Figure 2. Concentration-time profiles for total remdesivir (A), free remdesivir (B) GS-704277 (C), and GS-441524 (D). Data presented as median concentrations for each nominal time point by arm assuming a 1-hour infusion duration. Total remdesivir plot overlaid with half maximal effective concentration (EC50) in human airway epithelial (HAE) cells [15].

    Journal: The Journal of infectious diseases

    Article Title: Pharmacokinetics and Safety of Remdesivir in Pregnant and Non-Pregnant Women with COVID-19: Results from IMPAACT 2032.

    doi: 10.1093/infdis/jiae298

    Figure Lengend Snippet: Figure 2. Concentration-time profiles for total remdesivir (A), free remdesivir (B) GS-704277 (C), and GS-441524 (D). Data presented as median concentrations for each nominal time point by arm assuming a 1-hour infusion duration. Total remdesivir plot overlaid with half maximal effective concentration (EC50) in human airway epithelial (HAE) cells [15].

    Article Snippet: Plasma Pharmacokinetic Parameters for Remdesivir, GS-704277, and GS-441524 and Protein Binding by Study Arm PK Parameters Pregnant (n = 21) Nonpregnant (n = 22) GMR (90% CI) Infusion duration, ha 1.0 (0.5–1.28) 1.0 (0.5–2.0) ... Remdesivir AUClast, ng · h/mL 1132 (85.7) 1190 (82.7) 0.95 (0.65–1.38) AUC0-24h, ng · h/mL 1247 (87.2) 1303 (49.2) 0.96 (0.67–1.37) Cmax, ng/mL 1360 (108) 1237 (111) 1.10 (0.70–1.73) Tmax, h 1.17 (0.60–1.31) 1.08 (0.66–1.53) 0.86 (0.64–1.15) t1/2, h 1.01 (36.0) 1.09 (36.4) 0.92 (0.75–1.13) CL, L/h 80.2 (87.2) 79.6 (47.4) 1.01 (0.70–1.45) Vd, L 118 (89.8) 125 (57.4) 0.94 (0.63–1.39) GS-704277 AUClast, ng · h/mL 408 (47.8) 424 (35.5) 0.96 (0.78–1.18) AUC0-24h, ng · h/mL 454 (29.8) 437 (36.2) 1.04 (0.88–1.23) Cmax, ng/mL 217 (41.4) 213 (34.1) 1.02 (0.85–1.23) Tmax, h 1.18 (0.62–1.36) 1.08 (0.66–1.46) 0.99 (0.79–1.24) t1/2, h 1.33 (19.9) 1.23 (30.0) 1.08 (0.95–1.23) GS-441524 AUClast, ng · h/mL 1842 (31.9) 2065 (36.0) 0.89 (0.75–1.06) AUC0-24h, ng · h/mL 1836 (32.2) 2046 (37.7) 0.90 (0.75–1.07) Cmax, ng/mL 113 (27.8) 121 (32.0) 0.93 (0.80–1.09) Tmax, h 2.1 (2.0–3.4) 2.9 (2.0–4.7) 0.77 (0.61–.97) t1/2, h 20.0 (28.6) 20.3 (30.3) 0.96 (0.82–1.18) C24h, ng/mL 51.6 (38.5) 57.1 (44.1) 0.90 (0.73–1.12) Protein binding Remdesivir free fraction, % 3.43 (22.8) 3.22 (26.2) 1.06 (0.95–1.19) Albumin, g/L 28.0 (26.0–30.0) 36.0 (33.5–38.0) 0.70 (0.56–.86) AAG, mg/dL 94.6 (77.2–144.3) 124.4 (98.9–172.4) 0.73 (0.60–.88) Data presented as geometric mean (CV%), except infusion duration which is reported as median (range), and Tmax, albumin, and AAG which are reported as median (IQR).

    Techniques: Concentration Assay